AKT2 and diabetes mellitus: For example, recent studies have used metabolomics to reveal that restoring phenylalanine levels and modulating glutathione metabolism can identify drug targets such as AKT2 and PDK2 in diabetes and cancer models, thereby guiding precision drug design and repurposing [101,106].